DGIdb - ALEFACEPT Drug Record

ALEFACEPT chembl:CHEMBL1201571 ApprovedImmunotherapy

Alternate Names:

LFA3TIP
BG-9273
LFA-3TIP
AMEVIVE
BG-9712
ALEFACEPT
LFA-3CD2
ASP0485
chembl:CHEMBL1201571
rxcui:299635
chemidplus:222535-22-0
drugbank:00092

Drug Info:

Drug Class	immunosuppressive agents
Year of Approval	2003
FDA Approval	2003
Drug Class	fusion protein
Drug Indications	Immunosuppressive Agents

(1 More Sources)

Publications:

Ortonne, 2003, Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis., J Eur Acad Dermatol Venereol
Chamian et al., 2007, Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis., J Transl Med
da Silva et al., 2002, Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells., J. Immunol.
Larsen et al., 2007, Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept., Clin. Exp. Immunol.
Goedkoop et al., 2004, Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis., Arch. Dermatol. Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

ALEFACEPT CD2

Interaction Score: 92.74

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction T-cell surface antigen CD2 inhibitor

Trial Name -

PMIDs:
12795770 17555598 11970990 17403057 14968366 11752352

Sources:
TdgClinicalTrial ChemblInteractions TEND
ALEFACEPT CD58

Interaction Score: 15.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD

TEND: ALEFACEPT
- Version: 01-August-2011
Alternate Names:

ALEFACEPT Primary Drug Name

Drug Info:

Year of Approval 2003

Drug Class immunosuppressive agents

Publications:
TdgClinicalTrial: ALEFACEPT
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Immunosuppressive Agents

Drug Class fusion protein

FDA Approval 2003

Publications:
TTD: Alefacept
- Version: 2020.06.01
Alternate Names:

D09ZSO TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201571
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201571
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	T-cell surface antigen CD2 inhibitor
Trial Name	-

ALEFACEPT Drug Record

ALEFACEPT chembl:CHEMBL1201571 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

ALEFACEPT CD2

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction T-cell surface antigen CD2 inhibitor Trial Name -

PMIDs: 12795770 17555598 11970990 17403057 14968366 11752352

Sources: TdgClinicalTrial ChemblInteractions TEND

ALEFACEPT CD58

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

TEND: ALEFACEPT

Alternate Names: ALEFACEPT Primary Drug Name

Drug Info: Year of Approval 2003 Drug Class immunosuppressive agents

Publications:

TdgClinicalTrial: ALEFACEPT

Alternate Names:

Drug Info: Drug Indications Immunosuppressive Agents Drug Class fusion protein FDA Approval 2003

Publications:

TTD: Alefacept

Alternate Names: D09ZSO TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1201571

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1201571

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction T-cell surface antigen CD2 inhibitor

Trial Name -

PMIDs:
12795770 17555598 11970990 17403057 14968366 11752352

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Alternate Names:

ALEFACEPT Primary Drug Name

Drug Info:

Year of Approval 2003

Drug Class immunosuppressive agents

Drug Info:

Drug Indications Immunosuppressive Agents

Drug Class fusion protein

FDA Approval 2003

Alternate Names:

D09ZSO TTD Drug ID